Seeking Alpha

Bristol-Myers wins $752M patent infringement award against Gilead

|About: Bristol-Myers Squibb C... (BMY)|By: , SA News Editor

A Los Angeles jury has awarded $752M to Bristol-Myers Squibb (NYSE:BMY) in a dispute with Gilead Sciences (NASDAQ:GILD) over a CAR T patent exclusively licensed to BMY unit Juno Therapeutics.

The company claims that Gilead unit Kite's Yescarta (axicabtagene ciloleucel) infringes on the patent, licensed from Memorial Sloan Kettering Cancer Center, covering the use of CAR T-cell immunotherapy to treat cancer.

Gilead intends to appeal the verdict.

Try Seeking Alpha PREMIUM for unlimited analysis on BMY